Q1 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities research analysts at Roth Capital reduced their Q1 2025 earnings per share estimates for Nuvectis Pharma in a report issued on Tuesday, February 25th. Roth Capital analyst J. Aschoff now anticipates that the company will post earnings of ($0.28) per share for the quarter, down from their prior estimate of ($0.23). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.27) EPS, Q4 2025 earnings at ($0.27) EPS, FY2025 earnings at ($1.08) EPS, FY2026 earnings at ($1.12) EPS and FY2027 earnings at $1.33 EPS.

Separately, HC Wainwright cut their price objective on Nuvectis Pharma from $21.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday.

Nuvectis Pharma Stock Performance

NASDAQ:NVCT opened at $6.69 on Friday. The stock has a fifty day moving average price of $6.26 and a two-hundred day moving average price of $6.41. The stock has a market capitalization of $129.26 million, a price-to-earnings ratio of -5.77 and a beta of 0.22. Nuvectis Pharma has a 1 year low of $4.44 and a 1 year high of $12.10.

Nuvectis Pharma (NASDAQ:NVCT) last released its quarterly earnings results on Tuesday, March 4th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.08).

Insider Buying and Selling at Nuvectis Pharma

In related news, major shareholder Marlio Charles Mosseri acquired 240,000 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $1,200,000.00. Following the transaction, the insider now owns 2,884,121 shares in the company, valued at $14,420,605. This trade represents a 9.08 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last 90 days, insiders have bought 261,500 shares of company stock valued at $1,300,825. Insiders own 35.78% of the company’s stock.

Hedge Funds Weigh In On Nuvectis Pharma

A number of institutional investors have recently modified their holdings of the company. GSA Capital Partners LLP increased its position in Nuvectis Pharma by 3.7% during the third quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after purchasing an additional 1,790 shares during the last quarter. Baxter Bros Inc. grew its stake in Nuvectis Pharma by 20.0% during the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock worth $81,000 after buying an additional 2,500 shares during the period. Nations Financial Group Inc. IA ADV grew its stake in Nuvectis Pharma by 35.0% during the fourth quarter. Nations Financial Group Inc. IA ADV now owns 13,500 shares of the company’s stock worth $73,000 after buying an additional 3,500 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Nuvectis Pharma during the fourth quarter worth approximately $34,000. Finally, Northern Trust Corp grew its stake in Nuvectis Pharma by 68.7% during the fourth quarter. Northern Trust Corp now owns 25,725 shares of the company’s stock worth $139,000 after buying an additional 10,472 shares during the period. Institutional investors and hedge funds own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.